Tenaya director granted options for 120,000 shares

Tenaya Therapeutics director Jeffrey T. Walsh received a stock option grant covering 120,000 shares of common stock at an exercise price of $0.7989 per share.

Rhea-AI Filing Summary

Tenaya Therapeutics director Jeffrey T. Walsh received a stock option grant covering 120,000 shares of common stock at an exercise price of $0.7989 per share. The option was granted under the company’s 2021 Equity Incentive Plan, vests in full on May 28, 2027 (or earlier, before the next annual stockholder meeting), and expires on May 27, 2036. This filing reports an award of options rather than any open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 120,000 shares

Grant/Award 1 txn

Insider Walsh Jeffrey T.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy)	120,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 120,000 contracts (Direct)

Footnotes (1)

1. F1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

Key Figures

Option shares granted: 120,000 shares Exercise price: $0.7989 per share Underlying common shares: 120,000 shares +3 more

6 metrics

Option shares granted 120,000 shares Stock Option grant to Jeffrey T. Walsh

Exercise price $0.7989 per share Stock Option strike price

Underlying common shares 120,000 shares Common stock underlying the option

Post-transaction derivative holdings 120,000 options Total derivative shares following transaction

Vesting date May 28, 2027 Option vests in full or earlier before next annual meeting

Expiration date May 27, 2036 Option expiration

Key Terms

Stock Option (Right to buy), Equity Incentive Plan, vesting, service provider

4 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

Equity Incentive Plan financial

"Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan."

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

vesting financial

"Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

service provider financial

"subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tenaya Therapeutics (TNYA) director Jeffrey T. Walsh report in this Form 4?

Jeffrey T. Walsh reported receiving a stock option grant for 120,000 shares of Tenaya common stock. The award is documented as a derivative acquisition, not an open-market trade, and is tied to future vesting and service conditions under the company’s equity plan.

How many Tenaya Therapeutics (TNYA) shares are covered by Jeffrey Walsh’s new stock option?

The new stock option covers 120,000 shares of Tenaya Therapeutics common stock. These options give the right to buy shares at a fixed exercise price, subject to vesting and expiration terms described in the Form 4 and related footnote.

What is the exercise price and term of Jeffrey Walsh’s Tenaya Therapeutics (TNYA) stock option?

The option has an exercise price of $0.7989 per share and expires on May 27, 2036. This defines the price Walsh can pay for the shares and the final date the option can be exercised, assuming it has vested and other conditions are met.

When does Jeffrey Walsh’s Tenaya Therapeutics (TNYA) option vest according to the Form 4?

The option will vest in full on May 28, 2027, or earlier, the day immediately before the next annual stockholder meeting after the grant date. Vesting depends on Walsh continuing to be a service provider to Tenaya through the applicable vesting date.

Was Jeffrey Walsh’s Tenaya Therapeutics (TNYA) option grant part of a company equity plan?

Yes. The footnote states the option was granted under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Such plans set the terms for equity-based awards granted to eligible service providers of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/29/2026 - 07:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Jeffrey T.

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy)	$0.7989	05/28/2026		A		120,000		05/28/2027(1)	05/27/2036	Common Stock	120,000	$0	120,000	D

Explanation of Responses:

1. Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)